Early treatment of newly diagnosed COVID-19 patients with plasma extracted from individuals who have recovered from the disease reduces the need for hospitalization by more than 50%.
New Research Review Says HCQ Plus Zinc Reduces COVID-19 Deaths
Early on in the COVID-19 pandemic, doctors around the world reported high success rates using an inexpensive treatment protocol of hydroxychloroquine (HCQ) and zinc, typically in combination with an antibiotic to treat secondary bacterial infections.
The change came on the heels of a study by Oxford University in the United Kingdom that found HCQ underperformed its routine treatment protocols.
Unfortunately, problems in research methodologies assessing the effectiveness and risks of HCQ have left lingering doubts. Those problems include questionable dosing and the absence of zinc, arguably the more important element of any HCQ treatment protocol. The new review was published in the January 2021 issue of The American Journal of Medicine. It finds early use of HCQ and zinc can reduce hospitalizations and deaths from COVID-19.
Journal of Medicine Says HCQ + Zinc Reduces COVID Deaths
Early on in the COVID-19 pandemic, doctors around the world reported high success rates using an inexpensive treatment protocol of hydroxychloroquine (HCQ) and zinc, typically in combination with an antibiotic to treat secondary bacterial infections.
Almost immediately, government health agencies and mainstream media started attacking the treatment, going so far as to ban the prescription and use of HCQ for COVID-19 in some areas. Over time, it became painfully clear that a concerted and coordinated effort to prevent its use was afoot.
One of the most obvious reasons for why certain individuals and companies might want to prevent the use of an inexpensive generic drug is because it might eliminate the need for a vaccine or other antiviral medication under development.
US Health Authorities Asked by Three Distinguished Physicians to Review Medical Evidence for Prevention and Early Treatment of COVID-19 with Ivermectin
US Health Authorities Asked to Review Medical Evidence for Prevention and Early Treatment of COVID-19 with Ivermectin
The press conference was organized in Houston and featured Professor Joseph Varon, Professor Paul Marik and Professor Pierre Kory.
The three distinguished doctors had a simple and urgent message: it’s extremely important to take action to to reduce hospitalizations and deaths.
This they argue needs to be done with prevention / prophylaxis and early treatment.
They provided a review of existing studies, including the one in a French nursing home, that we also covered recently.